Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Resmed (RMD – Research Report) and MiMedx Group (MDXG – Research Report).
Resmed (RMD)
Jefferies analyst Matthew Taylor maintained a Hold rating on Resmed today and set a price target of $158.00. The company’s shares closed last Thursday at $138.73, close to its 52-week low of $136.02.
According to TipRanks.com, Taylor is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Resmed with a $188.20 average price target, which is a 34.6% upside from current levels. In a report issued on October 12, RBC Capital also downgraded the stock to Hold with a $202.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
MiMedx Group (MDXG)
In a report released today, Chase Knickerbocker from Craig-Hallum initiated coverage with a Buy rating on MiMedx Group and a price target of $12.00. The company’s shares closed last Thursday at $6.13.
According to TipRanks.com, Knickerbocker is a 3-star analyst with an average return of
MiMedx Group has an analyst consensus of Strong Buy, with a price target consensus of $12.25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RMD:
- ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2024
- RMD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Early notable gainers among liquid option names on October 23rd
- ResMed price target lowered to $220 from $230 at BofA
- ResMed price target lowered to $175 from $275 at Oppenheimer
